A month has gone by since the last earnings report for Halozyme Therapeutics (HALO) . Shares have lost about 13.1% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Halozyme Therapeutics, Inc. before we dive into how inv ...

Core Viewpoint - Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while the company searches for a permanent CFO [1] Group 1: Appointment Details - David Ramsay has over 30 years of strategic financial leadership experience in biotechnology and life sciences [1] - He previously served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which the company grew into a billion-dollar public biopharmaceutical entity [1] - Ramsay's prior experience includes serving as Senior Vice President and CFO of Bonti, Inc. until its acquisition by Allergan in October 2018 [1] Group 2: Executive Search - Halozyme is actively searching for a permanent CFO and has engaged a leading executive search firm to identify suitable candidates [1] - The search is focused on candidates with expertise in capital markets and strategic planning [1] Group 3: Company Overview - Halozyme is a biopharmaceutical company known for its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of drugs, improving patient convenience [1] - The technology has impacted over one million patients through ten commercialized products across more than 100 global markets [1] - Halozyme has expanded its technology portfolio with Hypercon™ and Surf Bio's hyperconcentration technology, enhancing the delivery of biologics [1]

Core Insights - The company is projecting total revenue for the year to be between $1.7 billion and $1.8 billion, representing a year-over-year growth of 22% to 30% [1] - The growth is primarily driven by royalties from partnered products and the ENHANZE platform, expected to generate approximately $1.1 billion to $1.2 billion, with a growth rate of 30% to 35% [2] - The adjusted EBITDA is also anticipated to be in the range of $1.1 billion to $1.2 billion, indicating strong profitability due to the royalty business [2] Revenue Drivers - The leading product contributing to growth is DARZALEX FASPRO, a subcutaneous version utilizing the ENHANZE technology [2] - Other significant contributors include argenx's VYVGART Hytrulo, which is experiencing strong adoption and growth, particularly with the prefilled syringe that incorporates ENHANZE [2] - Roche's Phesgo, used in breast cancer treatment, is also a key product driving revenue growth [2]

Halozyme Therapeutics Conference Call Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Conference Date**: March 11, 2026 - **Expected Revenue**: $1.7-$1.8 billion for 2026, representing a 22%-30% year-over-year growth [1][2] Key Products Driving Growth - **Main Revenue Drivers**: - **DARZALEX FASPRO**: Leading product with strong growth due to subcutaneous delivery [2] - **VYVGART HYTRULO**: Significant contributor with 100% year-over-year growth, driven by the adoption of the pre-filled syringe [8][10] - **Roche's Perjeta**: Transitioning to subcutaneous delivery, achieving a 52% conversion rate in the U.S. with a target of 60% by 2028 [6][5] Additional Product Opportunities - **Emerging Products**: Four recently launched products (Opdivo, OCREVUS, RYBREVANT, Tecentriq) expected to contribute significantly in 2026 [3][15] - **OCREVUS**: Roche's drug for multiple sclerosis, with a potential market expansion due to subcutaneous delivery, aiming for a $2 billion increase in sales [17][18] - **RYBREVANT**: Johnson & Johnson's lung cancer drug, transitioning from a 5-hour IV infusion to a 5-minute subcutaneous administration, aiming for a $5 billion brand [22][23] Strategic Partnerships and Deals - **New Partnerships**: Three new deals signed at the end of 2025, with expectations for at least three new deals in 2026 [27] - **Current Partner Expansion**: Existing partners are increasing their nominations for new drugs, indicating strong momentum [26] Development Pipeline - **Current Development**: Seven products in development with ENHANZE, including collaborations with argenx and Takeda [30] - **Future Projections**: Expectation of 40 approved or in-development drugs by 2028, with six new ENHANZE phase 1 starts this year [31] Litigation Update - **Merck Litigation**: Ongoing litigation regarding MDASE patents, with Halozyme confident in its position. Positive outcomes in Germany have halted Merck's launch of SubQ Keytruda [34][36] Acquisitions and Technology Expansion - **Recent Acquisitions**: - **Elektrofi**: Acquired for its Hypercon technology, enhancing subcutaneous delivery capabilities [37] - **Surf Bio**: Acquired for a different approach to hyperconcentration, expanding Halozyme's market opportunities [39] - **Market Acceptance**: Increased acceptance of subcutaneous delivery among partners, with expectations for 5-7 launches by the mid-2030s [44] Financial Guidance and Future Outlook - **Long-term Guidance**: Confidence in achieving $1 billion in royalties from Hypercon by the mid-2030s, based on partner plans and market acceptance [43][44] - **Growth Ambitions**: Continued focus on M&A to add assets with recurring royalty-like revenue, aiming for sustained growth [49][50]

Core Insights - Halozyme has been actively executing its business strategy and pursuing mergers and acquisitions to drive long-term growth [1] Group 1 - The company has made two recent acquisitions: Elektrofi and Surf Bio, which are expected to contribute to its growth strategy [2]

Halozyme Therapeutics Conference Call Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Date**: March 10, 2026 - **Event**: Leerink's Global Healthcare Conference Key Points Recent Acquisitions - Halozyme executed two acquisitions: Elektrofi and Surf Bio, aimed at enhancing subcutaneous drug delivery capabilities [2][4] - The acquisitions are expected to broaden and diversify offerings for partners in the biologics market [2][4] ENHANZE Technology - ENHANZE is a core technology that allows for large volume subcutaneous delivery of biologics, with 10 approved products and multiple in development [7] - The technology enables injections of 5-15 mL in minutes, enhancing patient convenience and treatment adherence [7][17] - The company anticipates signing 1-3 new ENHANZE deals in 2026, driven by increased interest in subcutaneous delivery [15][20] Hyperconcentration Technology - Hyperconcentration technology allows biologics to be concentrated by 3-4 times, facilitating smaller volume injections (2 mL or less) [4][11] - Clinical scale batches are expected to be ready this year, with two partners anticipated to enter Phase 1 testing [13] - The company projects achieving $1 billion in royalty revenue from Hyperconcentration by the mid-2030s [27][29] Market Trends and Growth Drivers - There is a growing recognition among pharmaceutical companies of the competitive advantages of subcutaneous delivery, leading to increased market interest [16][20] - Examples of successful subcutaneous products include Darzalex, VYVGART, and Ocrevus, which have seen significant market growth due to their delivery methods [17][18][19] M&A Strategy - Halozyme is focused on disciplined M&A, targeting opportunities that align with its business model of recurring, royalty-like revenues [21][25] - The company is patient in evaluating potential acquisitions, looking for businesses that complement its growth story [24][25] Financial Performance - In 2025, Halozyme reported a revenue growth of 38% to $1.4 billion, with royalties growing by 52% [38] - A one-time charge related to the Surf Bio acquisition impacted fourth-quarter EPS, but the company expects strong growth moving forward [38][39] Legal Matters - Halozyme is involved in litigation against Merck for patent infringement related to its Mdase patents, with potential for damages and injunctive relief [45][46] - The company does not expect significant impact from this litigation on its current projections [45] Future Outlook - The company anticipates doubling the number of commercialized and development products from about 20 to 40 by 2028 [54] - Strong growth is expected from existing products, including Darzalex, VYVGART, and RYBREVANT, which is projected to become a significant contributor due to its subcutaneous formulation [55][57] Regulatory Environment - Halozyme is monitoring the implications of the IRA (Inflation Reduction Act) on its products, expecting minimal impact due to the nature of its drug indications [33][36] Conclusion - Halozyme is positioned for significant growth through its innovative technologies, strategic acquisitions, and a strong market presence in subcutaneous drug delivery. The company is optimistic about its future prospects and continues to explore opportunities for expansion while maintaining a disciplined approach to M&A.

Core Insights - The U.S. FDA has approved TECVAYLI® in combination with DARZALEX FASPRO® for the treatment of adults with relapsed or refractory multiple myeloma, based on Phase 3 data showing significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard care [1][2] Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery technologies, including the ENHANZE® platform [1] - The company has commercialized ten products using ENHANZE® technology, impacting over one million patients globally [1] Product Approval Details - The approval of TECVAYLI® plus DARZALEX FASPRO® is based on the MajesTEC-3 study, which demonstrated an 83% reduction in the risk of disease progression or death compared to standard regimens, with a hazard ratio of 0.17 [1] - The three-year PFS rate for patients treated with the combination was reported at 83%, indicating a durable benefit [1] Technological Advancements - Halozyme's ENHANZE® technology facilitates subcutaneous delivery of drugs, reducing treatment burden and improving convenience for patients [1] - The company is expanding its drug delivery technology portfolio with Hypercon™ and Surf Bio's hyperconcentration technology, which aims to enhance the delivery of biologics [1] Financial Performance - Halozyme reported a record revenue of $1.4 billion for the full year 2025 and reiterated strong financial guidance for 2026 [2]

Core Insights - Halozyme has experienced significant activity recently, including three new ENHANZE deals and two acquisitions, indicating a strategic push for growth [2] - The company has updated its long-term guidance and reported Q4 earnings, suggesting a focus on financial performance and future projections [2] Company Growth Strategy - The next few years are positioned as a critical growth era for Halozyme, with key benchmarks expected to be established between now and 2028 [2] - Important value inflection points are anticipated, which will be crucial for assessing the company's growth trajectory [2]

Halozyme Therapeutics FY Conference Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Event**: FY Conference held on March 03, 2026 Key Industry Insights - **Subcutaneous Drug Delivery**: Halozyme is positioned as a leader in subcutaneous (sub-Q) drug delivery, with a focus on expanding its platform and solutions for pharmaceutical and biotech companies [3][4] - **Market Trends**: There is a significant shift from intravenous (IV) infusion therapies to sub-Q treatments, driven by patient convenience and the desire for at-home administration [5] Core Company Developments - **New Deals and Acquisitions**: - Signed 3 new ENHANZE deals across oncology, inflammatory bowel disease, and obesity [3] - Acquired Elektrofi and Surf Bio for their hyperconcentration technologies, which allow biologics to be concentrated from 100 mg/mL to 500 mg/mL, reducing injection volume significantly [4] - **Future Growth**: The company anticipates durable revenue growth, particularly from HyperCon technologies, with intellectual property lasting into the mid-2040s [5] Financial Guidance and Royalties - **Patent Status**: - EU patent extended through 2029, maintaining mid-single-digit royalty rates for Darzalex [6] - U.S. patent extension is not currently assumed in long-term guidance, but a positive outcome could provide upside [9] - **Royalty Revenue Projections**: - Expected to generate $1 billion in royalty revenue by 2035 from 5-7 products, including new HyperCon assets [14] Product Launch Dynamics - **VYVGART Hytrulo**: - Total revenues of $4.2 billion, with strong uptake in sub-Q formulations, particularly in myasthenia gravis and CIDP indications [27][29] - Anticipated to double in sales, driven by the convenience of sub-Q administration [30] - **Ocrevus and Opdivo**: - Ocrevus sub-Q expected to expand the market by $2 billion, with strong adoption rates [35] - Opdivo aims to convert 30%-40% of its market to sub-Q, supported by recent J-code adoption [38] Regulatory Environment - **CMS and IRA Impact**: - Limited exposure to Medicare, with only 20% of sales affected by the IRA, suggesting minimal impact on future revenue [43] - Ongoing discussions regarding the classification of fixed combinations and their implications for patent protections [40] M&A Strategy - **Future Acquisitions**: - Halozyme remains open to additional M&A opportunities that align with its high-margin royalty business model, particularly in drug delivery [19][20] - **Focus on Current Platforms**: - The primary focus for the year is maximizing the value of existing platforms while exploring new partnerships [18] Conclusion - Halozyme Therapeutics is strategically positioned for growth in the subcutaneous drug delivery market, with a robust pipeline of products and technologies. The company is focused on expanding its partnerships, enhancing its revenue streams, and navigating regulatory challenges effectively.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best cheap biotech stocks to buy now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received several bullish rating updates from analysts following its earnings release. Morgan Stanley lifted the price target on the stock to $94 from $78 on February 19, maintaining an Overweight rating on the shares after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported “strong” Q4 results. It told investors in a research note that it believes 2026 to be “another st ...